These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28402933)

  • 1. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.
    Yang C; Huang X; Liu H; Xiao F; Wei J; You L; Qian W
    Oncotarget; 2017 Jun; 8(24):39185-39197. PubMed ID: 28402933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy.
    Seo SU; Woo SM; Lee HS; Kim SH; Min KJ; Kwon TK
    Oncogene; 2018 Sep; 37(38):5205-5220. PubMed ID: 29849119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG‑132 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of the PTEN protein.
    Zhang J; Yang C; Zhou F; Chen X
    Oncol Rep; 2018 Jun; 39(6):2951-2959. PubMed ID: 29658600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
    Zhang X; Zhong S
    Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
    Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
    Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
    Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
    Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells.
    Srivastava RK; Li C; Khan J; Banerjee NS; Chow LT; Athar M
    Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24583-24592. PubMed ID: 31732667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
    Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
    Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.
    Wang Y; Xu W; Yan Z; Zhao W; Mi J; Li J; Yan H
    J Exp Clin Cancer Res; 2018 Mar; 37(1):63. PubMed ID: 29554968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in cellular model.
    Salama M; Elhussiny M; Magdy A; Omran AG; Alsayed A; Ashry R; Mohamed W
    Metab Brain Dis; 2018 Apr; 33(2):583-587. PubMed ID: 29080085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
    Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ
    Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment.
    Gao L; Li B; Yang G; Liu P; Lan X; Chang S; Tao Y; Xu Z; Xie B; Sun X; Wang Y; Hu L; Yu D; Xie Y; Bu W; Wu X; Zhu W; Shi J
    Cancer Lett; 2018 May; 421():135-144. PubMed ID: 29428642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
    Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
    Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function.
    Maimaitili Y; Inase A; Miyata Y; Kitao A; Mizutani Y; Kakiuchi S; Shimono Y; Saito Y; Sonoki T; Minami H; Matsuoka H
    Leuk Res; 2018 Nov; 74():68-74. PubMed ID: 30300823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
    Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
    Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of a dual mTORC1/2 inhibitor for the prevention of posterior capsule opacification: An in vitro study.
    Feng H; Yang Z; Bai X; Yang M; Fang Y; Zhang X; Guo Q; Ning H
    Int J Mol Med; 2018 Apr; 41(4):2099-2107. PubMed ID: 29344639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
    Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
    Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.